Compare Emerson Electric Co. (EMR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Inovio Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $163.79 (market cap $91.69B), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: Emerson Electric Co. is far larger — about 1167.3× Inovio Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EMR | INO | |
|---|---|---|
Market Cap | $91.69B | $78.55M |
Sector | Industrials | Health |
52-Week High | $164.38 | $2.87 |
52-Week Low | $123.30 | $0.66 |
Enterprise Value | $102.77B | $49.56M |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $164.02, up 3.36% with strong technical momentum and bullish analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding expectations. Recent acquisition of Glue Inc. enhances AI capabilities in test & measurement, supporting the raised 2026 outlook. Valuation metrics show P/E of 35.97 and P/S of 4.97, while profitability remains solid with 13.83% net margin.
EMR presents a favorable risk-reward profile with consensus price target of $171.33 offering 4.5% upside potential. Strong organic growth and AI integration drive optimism, though elevated valuation and overbought technical indicators warrant caution. The stock's proximity to 52-week highs suggests near-term consolidation may precede further gains based on execution of growth initiatives.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
